Press Releases

Press Releases

LEXINGTON, MA – March 31, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that RayBiotech, Inc., of Norcross, GA, has adopted its Simoa technology to deploy as part of their…
LEXINGTON, MA – August 5, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that the Journal of Clinical Microbiology has published a new study in which its Simoa (single molecule array) technology was used to develop a rapid, simple tool to allow diagnosis of…
January 14, 2016
Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing. 
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
May 16, 2017
CEO to discuss promising role of protein biomarkers in advancing detection and treatment of traumatic brain injury
Business Wire
Discussion will be led by Dr. Edward Wild and Lauren Byrne from the UCL Institute of Neurology, with introductory remarks from Kevin Hrusovsky, Executive Chairman and CEO, Quanterix